AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Spero Therapeutics Inc. (SPRO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.84

0.00 (0.26%)

At close: Feb 20, 2025, 3:59 PM

0.84

0.18%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	0.83
Market Cap	45.53M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.08
PE Ratio (ttm)	10.44
Forward PE	n/a
Analyst	Buy

Ask	0.87
Volume	60,271
Avg. Volume (20D)	240,681
Open	0.83
Previous Close	0.84
Day's Range	0.83 - 0.84
52-Week Range	0.74 - 1.89
Beta	undefined

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct actin...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 2, 2017

Employees 46

Stock Exchange NASDAQ

Ticker Symbol SPRO

Website https://sperotherapeutics.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SPRO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 498.66% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Spero Therapeutics Inc. is scheduled to release its earnings on Mar 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-1.53%

Spero Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

3 months ago

+1.55%

Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.

News

1 month ago · seekingalpha.com

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du...

1 month ago · zacks.com

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...